Abstract. The hydra neuropeptide, head activator, was detected in human placenta using radioimmunoassay. The placenta contained 11-68 fmol/g wet weight of head activator. The slope of the inhibition curve by placental extract in radioimmunoassay was identical to that of synthetic head activator. The molecular weight of the major immunoreactive head activator in placental extract corresponded to the synthetic head activator after Bio-Gel P-2 column chromatography. The peak of immunoreactive head activator in the extract emerged at the same retention time as that of the synthetic head activator on reversed-phase high-performance liquid chromatography. Head activator was localized histologically in trophoblasts of placenta by peroxidase-antiperoxidase staining techniques. The head activator staining was inhibited by the excessive synthetic head activator. The serum head activator level during pregnancy ranged from 9 to 31 pmol/l. A positive linear correlation was found between serum head activator content and gestational weeks.
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Head activator is an undecapeptide with a molecu¬ lar weight of 1125 daltons and an amino acid se¬ quence of pGlu-Pro-Pro-Gly-Gly-Ser-Lys-Val-lleLeu-Phe. Originally, it was discovered in the hydra and was found to exert a stimulatory effect on head specific growth and differentiation process (1) . It was also found in the human hypothalamus, intes¬ tine (2, 3) , and in human plasma at a concentration of 20-100 pmol/1 (4) . The physiological functions reported previously were stimulation of amylase secretion from rat pancreas (5) and the growth pro¬ moting effect of chick embryo brain cells (6) .
Whether head activator is also a differentiation factor of human fetal growth is unclear. The placenta regulates fetal growth through pregnancy by secreting many steroids and polypeptide hormones such as human chorionic gonadotropin and human placental lactogen. Neuropeptides such as gonadotropin-releasing hormone, somatostatin, thyrotropin-releasing hormone, and corticotropin-releasing hormone have also been found in placenta (7) .
Using a sensitive and specific radioimmunoas¬ say, we here demonstrate that the neuropeptide, head activator, occurs in human placenta.
Materials and Methods
The five placentas were obtained from both normal term deliveries and abortion in the second month of preg¬ nancy. 48 ml, and treated with 20 ml of ether. The aqueous layer was further treated with 20 ml of chloroform. The ex¬ tracts was lyophilized, and the lyophilized materials were used for characterization of head activator in placenta and for gel filtration or RP-HPLC. The same extraction procedure were also used for determining serum levels of head activator.
Head activator radioimmunoassay
The synthesis of head activator and the radioimmunoas¬ say for head activator, its sensitivity to and specificity for head activator has been described previously (9) . Briefly, there is no difference between head activator and Tyr -head activator in inhibition activity in the head activator radioimmunoassay. des Phe"-head activator, Arg'-head activator, which has the same N-terminal sequences (Arg'-Pro-Pro-Gly) as bradykinin, and Phe'-head activa¬ tor, which has the same amino acid sequence (Pro2-ProGly-Phe-Ser) as bradykinin, had an inhibition of less than 1% as compared with head activator and Tyr "-head ac¬ tivator. Bradykinin did not cross-react at all. The reaction mixture consisted of standard diluent buffer (0.5 ml), which was 10 mmol/1 phosphate buffer (pH 7.4) contain¬ ing 0.5% bovine serum albumin, 25 mmol/1 EDTA, and 0.15 mmol/1 NaCl, diluted anti-head activator serum (ASH-4) (0.1 ml), [125I]Tyr"-head activator (0.1 ml, 10 000 cpm), and sample (0.1 ml). The final dilution of anti-head activator serum was 24 000 fold. The binding activity (100% binding) of the tracer was 1300 cpm. The data of serum head activator were analysed by calculation of the correlation coefficient (r) and tested for statistical significance by Student's t-test.
Gel filtration
Lyophilized methanol extract of placenta, P912, was dis¬ solved in a buffer (5 ml) of 10 mmol/1 TRIS-HC1 (pH 7.4) and 0.1 mmol/1 NaCl. A part of the solution (4 ml) was applied to Bio-Gel P-2 column (2 x 77 cm), equilibrated with the same buffer, and eluted with the buffer at a flow rate of 20 ml/h. Fractions of 3 ml effluent were collected and 0.5 ml of each fraction was directly assayed for head activator.
RP-HPLC fractionation
Lyophilized methanol extract of placenta, P429, was dis¬ solved in 12% acetic acid (5 ml) fmol/g wet weight. As shown in Fig. 1 reaction was observed in syncytial cells (Fig. 4) Correlation between head activator content in pregnant serum (y) and gestational weeks (x). y=12. (4) . The difference may be due to the specificity of the head activator radioimmu¬ noassay system used.
To examine the physiological role of placental head activator during pregnancy, the head activa¬ tor levels were determined in serum at various ges¬ tational months and in the umbilical cord blood serum at normal delivery. Head activator levels in term maternal serum were significantly higher than in serum from non-pregnant women and in umbilical cord serum. However, the head activator levels in maternal serum at week 40 of a twin and triplet pregnancy remained within the range of normal pregnancy, indicating that the maternal serum head activator level is not dependent on the weight of the placenta. No difference was observed between head activator levels in umbilical cord blood serum and head activator levels in serum of non-pregnant women. It appeared that placental head activator was not actively secreted into fetal circulation, or it was rapidly degraded by serum proteases.
The factors regulating the growth of human pla¬ centa and fetus are still unclear. Being a neuropeptide, the placental head activator might have an autocrine or endocrine effect on the placenta and fetus.
